Frontlight ResearchEarly access
CompletedPhase 4
Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults
Key facts
- Who runs it
- Korea University Guro Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 121 people enrolled
- Started
- 25 Oct 2025
- Ended
- 31 Aug 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard-Dose Influenza Vaccine
- MF59-Adjuvanted Influenza Vaccine
- High-Dose Influenza Vaccine
- Record updated
- 4 September 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age ≥65 years
- Able and willing to provide informed consent
Who cannot take part
- Uncontrolled chronic medical conditions
- Laboratory-confirmed influenza infection within the past 6 months
- Influenza vaccination within the past 6 months
- Immunocompromised status
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, randomized, open-label clinical study aims to evaluate the immunogenicity and underlying immune mechanisms of different influenza vaccine formulations in adults aged ≥65 years. Additionally, the study investigates the role of the gut microbiome in modulating vaccine-induced immune responses and durability.
The 3 groups in the trial
- Standard-Dose Influenza VaccineExisting treatment, for comparison
Intervention: Standard-dose quadrivalent influenza vaccine (Vaxigrip®) Dose: 0.5 mL intramuscular injection, single dose
- MF59-Adjuvanted Influenza VaccineExisting treatment, for comparison
Intervention: MF59-adjuvanted vaccine (FLUAD®) Dose: 0.5 mL intramuscular injection, single dose
- High-Dose Influenza VaccineExisting treatment, for comparison
Intervention: High-dose influenza vaccine (Efluelda®) Dose: 0.7 mL intramuscular injection, single dose
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 September 2026